At OncoVanta Therapeutics, we specialize in the development of TCR-T cell therapies that are designed to precisely target mutant TP53 cancers. Our innovative approach harnesses the power of the immune system to specifically identify and destroy cancer cells while minimizing harm to healthy tissues. This targeted therapy represents a significant advancement in cancer treatment, offering patients a safe and effective alternative to traditional methods. By focusing on precision, we not only aim to improve patient outcomes but also to enhance the overall quality of life for those battling these challenging cancers.